Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A Combination Therapy for Asthma

Author(s): Alberto Papi*, Konstantinos Kostikas, Ivan Nikolaev and Ioannis Kottakis

Volume 18, Issue 2, 2022

Published on: 24 March, 2022

Page: [77 - 85] Pages: 9

DOI: 10.2174/1573398X18666220217151845

open access plus

Abstract

Despite the wide range of available therapies, asthma remains uncontrolled in 40-65% of patients for a number of different reasons. Treatment with an inhaled corticosteroid (ICS) is recommended in the Global Initiative for Asthma 2021 report for patients across all asthma severities, with treatment options combining an ICS with a long-acting β2-agonist (LABA) or a LABA and a long-acting muscarinic antagonist (LAMA), depending on disease severity. Based on this, the availability of a single inhaler fixed-dose ICS/LABA/LAMA combination is a major need in asthma management. Indacaterol acetate/glycopyrronium bromide/mometasone furoate has been developed as a once-daily inhaled asthma treatment that combines an ICS (mometasone furoate), a LABA (indacaterol acetate), and a LAMA (glycopyrronium bromide) in a formulation delivered using the dry powder inhaler Breezhaler®, for patients with uncontrolled asthma on medium- or high-dose ICS/LABA. This article provides an overview of the different and complementary mechanisms of action and the clinical effectiveness of the monocomponents of the indacaterol/glycopyrronium/ mometasone furoate fixed combination and highlights the benefits of using the three agents in combination in patients with moderate and severe asthma.

Keywords: Asthma, indacaterol, glycopyrronium, mometasone, combination therapy, Breezhaler®.

« Previous Next »
Graphical Abstract

[1]
Aalbers R, Vogelmeier C, Kuna P. Achieving asthma control with ICS/LABA: A review of strategies for asthma management and preven-tion. Respir Med 2016; 111: 1-7.
[http://dx.doi.org/10.1016/j.rmed.2015.11.002] [PMID: 26614594]
[2]
Buhl R, Heaney LG, Loefroth E, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med 2020; 162: 105859.
[http://dx.doi.org/10.1016/j.rmed.2019.105859] [PMID: 31916534]
[3]
Demoly P, Paggiaro P, Plaza V, et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev 2009; 18(112): 105-12.
[http://dx.doi.org/10.1183/09059180.00001209] [PMID: 20956130]
[4]
Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21(123): 66-74.
[http://dx.doi.org/10.1183/09059180.00008111] [PMID: 22379176]
[5]
Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: A cross-sectional analysis. NPJ Prim Care Respir Med 2017; 27(1): 17.
[http://dx.doi.org/10.1038/s41533-017-0014-1] [PMID: 28270657]
[6]
Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100(7): 1139-51.
[http://dx.doi.org/10.1016/j.rmed.2006.03.031] [PMID: 16713224]
[7]
Stanford RH, Gilsenan AW, Ziemiecki R, Zhou X, Lincourt WR, Ortega H. Predictors of uncontrolled asthma in adult and pediatric pa-tients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma 2010; 47(3): 257-62.
[http://dx.doi.org/10.3109/02770900903584019] [PMID: 20210612]
[8]
Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31(2): 320-5.
[http://dx.doi.org/10.1183/09031936.00039707] [PMID: 17959642]
[9]
Menzies-Gow A, Chiu G. Perceptions of asthma control in the United Kingdom: A cross-sectional study comparing patient and healthcare professionals’ perceptions of asthma control with validated ACT scores. NPJ Prim Care Respir Med 2017; 27(1): 48.
[http://dx.doi.org/10.1038/s41533-017-0050-x] [PMID: 28801654]
[10]
Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6(1): 13.
[http://dx.doi.org/10.1186/1471-2466-6-13] [PMID: 16772035]
[11]
Global Initiatives for Asthma. 2021 GINA Report. Global Strategy for Asthma Management and Prevention. Available from: https://ginasthma.org/gina-reports/[Accessed 24 August 2021]
[12]
Cazzola M, Puxeddu E, Matera MG, Rogliani P. A potential role of triple therapy for asthma patients. Expert Rev Respir Med 2019; 13(11): 1079-85.
[http://dx.doi.org/10.1080/17476348.2019.1657408] [PMID: 31422716]
[13]
Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003; 139(5 Pt 1): 359-70.
[http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00012] [PMID: 12965945]
[14]
Pera T, Penn RB. Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol 2014; 16: 72-81.
[http://dx.doi.org/10.1016/j.coph.2014.03.005] [PMID: 24747364]
[15]
Kistemaker LEM, Bos IST, Menzen MH, Maarsingh H, Meurs H, Gosens R. Combination therapy of tiotropium and ciclesonide attenuates airway inflammation and remodeling in a guinea pig model of chronic asthma. Respir Res 2016; 17(1): 13.
[http://dx.doi.org/10.1186/s12931-016-0327-6] [PMID: 26846267]
[16]
Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40(5): 1106-14.
[http://dx.doi.org/10.1183/09031936.00040712] [PMID: 23060624]
[17]
Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in japan: a randomised, placebo-controlled study. PLoS One 2015; 10(4): e0124109.
[http://dx.doi.org/10.1371/journal.pone.0124109] [PMID: 25894430]
[18]
Asmanex® Twisthaler® Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021067s003lbl.pdf[Accessed 24 August 2021].
[19]
Asmanex® Twisthaler® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/6753/smpc [Accessed 24 August 2021].
[20]
Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol 2015; 80(3): 372-80.
[http://dx.doi.org/10.1111/bcp.12637] [PMID: 25808113]
[21]
Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticoster-oids to asthma. Eur Respir J 2006; 28(5): 1042-50.
[http://dx.doi.org/10.1183/09031936.00074905] [PMID: 17074919]
[22]
Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998; 48(9): 956-60.
[PMID: 9793625]
[23]
Valotis A, Neukam K, Elert O, Högger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 2004; 93(5): 1337-50.
[http://dx.doi.org/10.1002/jps.20049] [PMID: 15067709]
[24]
McCormack PL, Plosker GL. Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents. Drugs 2006; 66(8): 1151-68.
[http://dx.doi.org/10.2165/00003495-200666080-00011] [PMID: 16789800]
[25]
Bensch GW, Prenner B, Berkowitz R, Galant S, Ramsdell J, Lutsky B. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006; 96(4): 533-40.
[http://dx.doi.org/10.1016/S1081-1206(10)63547-8] [PMID: 16680923]
[26]
Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory func-tion and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000; 106(5): 852-60.
[http://dx.doi.org/10.1067/mai.2000.110798] [PMID: 11080706]
[27]
Karpel JP, Busse WW, Noonan MJ, Monahan ME, Lutsky B, Staudinger H. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005; 39(12): 1977-83.
[http://dx.doi.org/10.1345/aph.1G410] [PMID: 16264062]
[28]
Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000; 106(3): 485-92.
[http://dx.doi.org/10.1067/mai.2000.109431] [PMID: 10984368]
[29]
Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001; 86(1): 36-43.
[http://dx.doi.org/10.1016/S1081-1206(10)62353-8] [PMID: 11206236]
[30]
D’Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005; 21(8): 1281-9.
[http://dx.doi.org/10.1185/030079905X56402] [PMID: 16083538]
[31]
Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asth-ma. Ann Allergy Asthma Immunol 2000; 84(4): 417-24.
[http://dx.doi.org/10.1016/S1081-1206(10)62275-2] [PMID: 10795650]
[32]
Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhal-er. Respir Med 1999; 93(9): 603-12.
[http://dx.doi.org/10.1016/S0954-6111(99)90099-9] [PMID: 10542973]
[33]
Bousquet J, D’Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16(5): 808-16.
[http://dx.doi.org/10.1183/09031936.00.16580800] [PMID: 11153576]
[34]
Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone di-propionate. Ann Allergy Asthma Immunol 2001; 86(2): 203-10.
[http://dx.doi.org/10.1016/S1081-1206(10)62692-0] [PMID: 11258691]
[35]
O’Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001; 86(4): 397-404.
[http://dx.doi.org/10.1016/S1081-1206(10)62485-4] [PMID: 11345282]
[36]
Wardlaw A, Larivee P, Eller J, Cockcroft DW, Ghaly L, Harris AG. Efficacy and safety of mometasone furoate dry powder inhaler vs. fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004; 93(1): 49-55.
[http://dx.doi.org/10.1016/S1081-1206(10)61446-9] [PMID: 15281471]
[37]
Corren J, Berkowitz R, Murray JJ, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003; 57(7): 567-72.
[PMID: 14529054]
[38]
Harnest U, Price D, Howes T, Sussman G. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninfe-riority trial. J Asthma 2008; 45(3): 215-20.
[http://dx.doi.org/10.1080/02770900801890646] [PMID: 18415829]
[39]
Yang D, Wang J, Bunjhoo H, Xiong W, Xu Y, Zhao J. Comparison of the efficacy and safety of mometasone furoate to other inhaled ster-oids for asthma: A meta-analysis. Asian Pac J Allergy Immunol 2013; 31(1): 26-35.
[PMID: 23517391]
[40]
Holgate ST, Arshad H, Stryszak P, Harrison JE. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. J Allergy Clin Immunol 2000; 105(5): 906-11.
[http://dx.doi.org/10.1067/mai.2000.105709] [PMID: 10808170]
[41]
Inman MD, Watson RM, Rerecich T, et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001; 164(4): 569-74.
[http://dx.doi.org/10.1164/ajrccm.164.4.2007063] [PMID: 11520717]
[42]
Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187(7): 690-6.
[http://dx.doi.org/10.1164/rccm.201209-1739PP] [PMID: 23348973]
[43]
Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of ac-tion. J Pharmacol Exp Ther 2006; 317(2): 762-70.
[http://dx.doi.org/10.1124/jpet.105.098251] [PMID: 16434564]
[44]
Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M. Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi. Eur Respir J 2007; 29(3): 575-81.
[http://dx.doi.org/10.1183/09031936.00032806] [PMID: 17135231]
[45]
Baur F, Beattie D, Beer D, et al. The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. J Med Chem 2010; 53(9): 3675-84.
[http://dx.doi.org/10.1021/jm100068m] [PMID: 20402514]
[46]
Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38(5): 533-47.
[http://dx.doi.org/10.1016/j.ejps.2009.10.001] [PMID: 19819331]
[47]
Roig J, Hernando R, Mora R. Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist. Open Respir Med J 2009; 3(1): 27-30.
[http://dx.doi.org/10.2174/1874306400903010027] [PMID: 19452036]
[48]
Seth HD, Sultan S, Gotfried MH. Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease. J Thorac Dis 2013; 5(6): 806-14.
[PMID: 24409359]
[49]
Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B. Onset of action of indacaterol in patients with COPD: comparison with salbut-amol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010; 5: 311-8.
[PMID: 20856830]
[50]
Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: com-parison with placebo and formoterol. Curr Med Res Opin 2009; 25(2): 463-70.
[http://dx.doi.org/10.1185/03007990802675096] [PMID: 19192991]
[51]
Laforce C, Aumann J, de Teresa Parreño L, et al. Sustained 24-hour efficacy of once daily indacaterol (300μg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study. Pulm Pharmacol Ther 2011; 24(1): 162-8.
[http://dx.doi.org/10.1016/j.pupt.2010.06.005] [PMID: 20619353]
[52]
Beasley RW, Donohue JF, Mehta R, et al. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: A double-blind randomised controlled trial. BMJ Open 2015; 5(2): e006131.
[http://dx.doi.org/10.1136/bmjopen-2014-006131] [PMID: 25649209]
[53]
Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007; 29(5): 871-8.
[http://dx.doi.org/10.1183/09031936.00060006] [PMID: 17251236]
[54]
Onbrez® Breezhaler®. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/onbrez-breezhaler-epar-product-information_en.pdf [Accessed 24 August 2021].
[55]
Arcapta® Neohaler®. Prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf [Accessed 24 August 2021].
[56]
Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010; 104(12): 1869-76.
[http://dx.doi.org/10.1016/j.rmed.2010.08.010] [PMID: 20850959]
[57]
Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65(6): 473-9.
[http://dx.doi.org/10.1136/thx.2009.125435] [PMID: 20522841]
[58]
Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropi-um. Am J Respir Crit Care Med 2010; 182(2): 155-62.
[http://dx.doi.org/10.1164/rccm.200910-1500OC] [PMID: 20463178]
[59]
Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study. Respir Med 2011; 105(5): 719-26.
[http://dx.doi.org/10.1016/j.rmed.2011.02.008] [PMID: 21367594]
[60]
Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: A placebo-controlled comparison. Eur Respir J 2011; 37(2): 273-9.
[http://dx.doi.org/10.1183/09031936.00045810] [PMID: 20693243]
[61]
Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: A network meta-analysis. Int J Chron Obstruct Pulmon Dis 2017; 12: 367-81.
[http://dx.doi.org/10.2147/COPD.S119908] [PMID: 28176892]
[62]
Metaxas EI, Balis E. The safety of indacaterol for the treatment of COPD. Expert Opin Drug Saf 2018; 17(6): 637-42.
[http://dx.doi.org/10.1080/14740338.2018.1472233] [PMID: 29741108]
[63]
Tashkin DP. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2010; 11(12): 2077-85.
[http://dx.doi.org/10.1517/14656566.2010.499358] [PMID: 20642373]
[64]
Miller D, Jauernig J, Vaidya S, et al. Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma pa-tients. Eur Respir J 2019; 54(Suppl. 63).: PA2542.
[65]
Carter NJ. Inhaled glycopyrronium bromide: A review of its use in patients with moderate to severe chronic obstructive pulmonary dis-ease. Drugs 2013; 73(7): 741-53.
[http://dx.doi.org/10.1007/s40265-013-0058-7] [PMID: 23677802]
[66]
Riario-Sforza GG, Ridolo E, Riario-Sforza E, Incorvaia C. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med 2015; 9(1): 23-33.
[http://dx.doi.org/10.1586/17476348.2015.996133] [PMID: 25547422]
[67]
Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: A system-atic review of clinical benefit. Int J Chron Obstruct Pulmon Dis 2012; 7: 673-8.
[http://dx.doi.org/10.2147/COPD.S35990] [PMID: 23055716]
[68]
Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 729-41.
[http://dx.doi.org/10.2147/COPD.S36001] [PMID: 23118536]
[69]
Sykes DA, Dowling MR, Leighton-Davies J, et al. The Influence of receptor kinetics on the onset and duration of action and the therapeu-tic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012; 343(2): 520-8.
[http://dx.doi.org/10.1124/jpet.112.194456] [PMID: 22854200]
[70]
Haddad E-B, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG. Pharmacological characterization of the muscarinic receptor antago-nist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol 1999; 127(2): 413-20.
[http://dx.doi.org/10.1038/sj.bjp.0702573] [PMID: 10385241]
[71]
Verkindre C, Fukuchi Y, Flémale A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010; 104(10): 1482-9.
[http://dx.doi.org/10.1016/j.rmed.2010.04.006] [PMID: 20541381]
[72]
Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012; 7: 503-13.
[http://dx.doi.org/10.2147/COPD.S32451] [PMID: 22973092]
[73]
D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011; 12(1): 156.
[http://dx.doi.org/10.1186/1465-9921-12-156] [PMID: 22151296]
[74]
Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting musca-rinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014; 14(1): 4.
[http://dx.doi.org/10.1186/1471-2466-14-4] [PMID: 24438744]
[75]
Wang C, Sun T, Huang Y, et al. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int J Chron Obstruct Pulmon Dis 2015; 10: 57-68.
[PMID: 25609940]
[76]
Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asth-ma. Chest 2005; 128(4): 1974-9.
[http://dx.doi.org/10.1378/chest.128.4.1974] [PMID: 16236844]
[77]
Blais CM, Davis BE, Cockcroft DW. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacho-line dose-response curve of mild asthmatics: A randomized three-way crossover study. Respir Res 2017; 18(1): 146.
[http://dx.doi.org/10.1186/s12931-017-0628-4] [PMID: 28768531]
[78]
Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrroni-um against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med 2016; 118: 96-101.
[http://dx.doi.org/10.1016/j.rmed.2016.07.017] [PMID: 27578477]
[79]
Kerwin E, Wachtel A, Sher L, et al. Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial. Respir Med 2018; 139: 39-47.
[http://dx.doi.org/10.1016/j.rmed.2018.04.013] [PMID: 29858000]
[80]
Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticoster-oids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016; 1(1): CD011721.
[http://dx.doi.org/10.1002/14651858.CD011721.pub2] [PMID: 26798035]
[81]
Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011; 105(3): 337-42.
[http://dx.doi.org/10.1016/j.rmed.2010.10.021] [PMID: 21144724]
[82]
Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010; 23(5): 438-44.
[http://dx.doi.org/10.1016/j.pupt.2010.04.005] [PMID: 20416390]
[83]
Arievich H, Overend T, Renard D, et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med 2012; 12(1): 74.
[http://dx.doi.org/10.1186/1471-2466-12-74] [PMID: 23217058]
[84]
Mahler DA, Gifford AH, Satti A, et al. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3). Respir Med 2016; 115: 39-45.
[http://dx.doi.org/10.1016/j.rmed.2016.03.015] [PMID: 27215502]
[85]
Seebri Breezhaler Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/files/pil.2840.pdf [Accessed 24 August 2021].
[86]
Ultibro Breezhaler Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/3496/smpc [Accessed 24 August 2021].
[87]
Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42(6): 1484-94.
[http://dx.doi.org/10.1183/09031936.00200212] [PMID: 23722616]
[88]
Tashkin DP, Gross NJ. Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2018; 13: 1873-88.
[http://dx.doi.org/10.2147/COPD.S162646] [PMID: 29928118]
[89]
Vaidya S, Ziegler D, Tanase A-M, et al. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers. Pulm Pharmacol Ther 2021; 70: 102019.
[http://dx.doi.org/10.1016/j.pupt.2021.102019] [PMID: 33771722]
[90]
Vaidya SS, Khindri S, Calder N, et al. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects. Pulm Pharmacol Ther 2016; 37: 30-6.
[http://dx.doi.org/10.1016/j.pupt.2016.01.004] [PMID: 26845343]
[91]
Tillmann H-C, Ethell B, Abdallah N, et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects. Eur Respir J 2019; 54(Suppl. 63).: PA2540.
[92]
van Zyl-Smit RN, Krüll M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): A randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med 2020; 8(10): 987-99.
[http://dx.doi.org/10.1016/S2213-2600(20)30178-8] [PMID: 32653075]
[93]
Kornmann O, Mucsi J, Kolosa N, et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings. Respir Med 2020; 161: 105809.
[http://dx.doi.org/10.1016/j.rmed.2019.105809] [PMID: 32056721]
[94]
Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): A randomised, double-blind, controlled phase 3 study. Lancet Respir Med 2020; 8(10): 1000-12.
[http://dx.doi.org/10.1016/S2213-2600(20)30190-9] [PMID: 32653074]
[95]
Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med 2020; 170: 106021.
[http://dx.doi.org/10.1016/j.rmed.2020.106021] [PMID: 32843164]
[96]
European Medicines Agency Enezair Breezhaler Summary of Product Characteristics Available from: https://www.ema.europa. eu/en/medicines/human/EPAR/enerzair-breezhaler
[97]
Chapman KR, Van Zyl-Smit RN, Kerstjens HAM, et al. Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrro-nium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study. Eur Respir J 2021.: OA1489.
[98]
Durrington HJ, Farrow SN, Loudon AS, et al. The circadian clock and asthma. Thorax 2014; 69: 90-2.
[http://dx.doi.org/10.1136/thoraxjnl-2013-203482]
[99]
Beier J, Watz H, Scholz V, et al. The efficacy of the combination indacaterol/glycopyrronium/mometasone furoate is independent of time of dosing in patients with asthma. Am J Respir Crit Care Med 2019; 199: A1277-8.

Rights & Permissions Print Cite
Article Metrics
109
1
© 2024 Bentham Science Publishers | Privacy Policy